Ultragenyx Pharmaceutical (RARE) said Wednesday it has agreed to sell a rare pediatric disease priority review voucher for $203 million, subject to customary closing conditions and an antitrust waiting period.
The voucher came with US approval of Fayuvi, the first treatment cleared for the rare childhood disorder Sanfilippo syndrome type A, the company said.
Such vouchers are granted by the US Food and Drug Administration and can be sold or redeemed to speed up a regulatory review of a different drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments